Complex Relationships Between Homologous Recombination Deficiency (HRD) Score and Mutational Status of Homologous Recombination Repair (HRR) Genes in Prostate Carcinomas

Homologous recombination deficiency (HRD) resulting from inactivation of <i>BRCA1/2</i> genes promotes chromosomal instability and renders tumor cells susceptible to platinum derivatives and PARP inhibitors (PARPi). The contribution of alterations in other homologous recombination repair (HRR) genes to HRD remains understudied. This investigation aimed to analyze the spectrum of mutations in 34 HRR genes in prostate carcinomas (PCs) and study the relationship between HRR status and HRD. HRR mutations and HRD scores were examined by NGS in 1131 and 680 PCs, respectively. Pathogenic or likely pathogenic variants in HRR genes were detected in 216/1131 cases (19.1%). HRD, defined by an HRD score cut-off of ≥42, was observed more frequently in HRR-mutated than in wild-type tumors (23/120 (19.2%) vs. 29/560 (5.2%), <i>p</i> < 0.0001). The highest HRD scores were detected in PCs with biallelic inactivation of the <i>BRCA2</i> or <i>PALB2</i> genes, as well as in tumors with <i>BRIP1</i> mutations. HRD was also occasionally seen in PCs with <i>ATM</i>, <i>NBN, FANCM</i>, <i>BRCA1</i> and <i>CDK12</i> alterations, but never in cases with <i>CHEK2</i> mutations. HRD was significantly more associated with aggressive PC features than HRR mutations. The majority of <i>CDK12</i>-mutated tumors exhibited a distinct type of copy number variations (CNV)-a tandem duplication phenotype. Our study suggests that the selection of PC patients for PARPi treatment requires a significant revision of existing attitudes towards tumor genetic profiling.

Authors

Institutions

Publication Details

Journal
International Journal of Molecular Sciences
Published
2025-12-08
DOI
https://doi.org/10.3390/ijms262411851
Primary Topic
PARP inhibition in cancer therapy
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Complex Relationships Between Homologous Recombination Deficiency (HRD) Score and Mutational Status of Homologous Recombination Repair (HRR) Genes in Prostate Carcinomas

A.S. Peremyshlenko, Ekatherina Sh. Kuligina, A. V. Agaeva, Anna D. Shestakova et al.
International Journal of Molecular Sciences
PARP inhibition in cancer therapy
article

Complex Relationships Between Homologous Recombination Deficiency (HRD) Score and Mutational Status of Homologous Recombination Repair (HRR) Genes in Prostate Carcinomas

A.S. Peremyshlenko, Ekatherina Sh. Kuligina, A. V. Agaeva, Anna D. Shestakova, Анна Петровна Соколенко, Ekaterina A. Otradnova, Р. В. Орлова, Nadezhda S. Morozova, Mhitar M. Grigoryan, Vladimir Krivtsov, A. Dzyuba, Евгений Наумович Имянитов, А. А. Белоусов, Aglaya G. Iyevleva, Irina K. Amirkhanova, M. Nechaeva, С. В. Попов, А. В. Орлов, Светлана Николаевна Алексахина, А. М. Belyaev, Vladislav F. Kutyan, Maria V. Syomina, Natalya V. Prokudina, Alisa S. Nikitina, Kira A. Kashko, Elena N. Vorobyeva, Lyubov I. Zatulivetrova, Pavel V. Vyazovcev, Tatyana Yu. Luchkova, Irina Yu. Povorina, Aryuna B. Gomboeva, Natalya A. Butunina, Nadezhda V. Kryukova, Olga M. Gudkova, Oksana N. Shkodenko, Andrey V. Levushkin, Daniil O. Moiseev, Demyan V. Gubarev, Spartak I. Lefterov, Olga I. Shchiglik, Timur M. Topuzov
article en

Abstract

Homologous recombination deficiency (HRD) resulting from inactivation of <i>BRCA1/2</i> genes promotes chromosomal instability and renders tumor cells susceptible to platinum derivatives and PARP inhibitors (PARPi). The contribution of alterations in other homologous recombination repair (HRR) genes to HRD remains understudied. This investigation aimed to analyze the spectrum of mutations in 34 HRR genes in prostate carcinomas (PCs) and study the relationship between HRR status and HRD. HRR mutations and HRD scores were examined by NGS in 1131 and 680 PCs, respectively. Pathogenic or likely pathogenic variants in HRR genes were detected in 216/1131 cases (19.1%). HRD, defined by an HRD score cut-off of ≥42, was observed more frequently in HRR-mutated than in wild-type tumors (23/120 (19.2%) vs. 29/560 (5.2%), <i>p</i> < 0.0001). The highest HRD scores were detected in PCs with biallelic inactivation of the <i>BRCA2</i> or <i>PALB2</i> genes, as well as in tumors with <i>BRIP1</i> mutations. HRD was also occasionally seen in PCs with <i>ATM</i>, <i>NBN, FANCM</i>, <i>BRCA1</i> and <i>CDK12</i> alterations, but never in cases with <i>CHEK2</i> mutations. HRD was significantly more associated with aggressive PC features than HRR mutations. The majority of <i>CDK12</i>-mutated tumors exhibited a distinct type of copy number variations (CNV)-a tandem duplication phenotype. Our study suggests that the selection of PC patients for PARPi treatment requires a significant revision of existing attitudes towards tumor genetic profiling.

International Journal of Molecular SciencesVol. 26(24)
Penza State University (RU), Vologda State University (RU), Buryat State University (RU), Severance Hospital (KR), Stavropol Regional Clinical Oncology Center (RU), Leningrad Regional Cancer Center (RU), Saratov Research Institute of Traumatology and Orthopedics (RU), Institute of Oncology NN Petrov (RU), City Clinical Oncology Center (RU), Pyatigorsk Oncology Center (RU), Penza State University of Architecture and Construction (RU), Oncological Dispensary No. 2 (RU), Guz "Tul'skiy Oblastnoy Onkologicheskiy Dispanser (RU), Saint Luke's Hospital (US), Pskov State University (RU), Saratov Research Center (RU), Arkhangel'skiy Klinicheskiy Onkologicheskiy Dispanser (RU), Chelyabinsk Regional Clinical Oncology Center (RU), Karelian Research Centre (RU), Pskov State Pedagogical Institute (RU), Krasnodar Higher Military School named after General of the Army S. Shtemenko (RU), International Institute of Management Arkhangelsk (RU), Saint Petersburg State Pediatric Medical University (RU), Kaliningrad State Technical University (RU)
Russian Science Foundation, National Medical Research Council
Openalex Percentile: Top 46%
PARP inhibition in cancer therapy
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.